India's first indigenous bird flu vaccine to launch Nov 20, developed by ICAR-NIHSAD
Synopsis
Key Takeaways
Agriculture Minister Shivraj Singh Chouhan is set to unveil India's first indigenously developed bird flu vaccine — the 'Inactivated H5N1' avian influenza vaccine for chickens — on 20 November 2026, according to an official statement released on Wednesday. The vaccine, developed by ICAR-NIHSAD Bhopal, targets the Clade 2.3.2.1a H5N1 virus strain, which is responsible for most bird flu outbreaks in Indian poultry.
A First for Indian Poultry Science
Until now, no specific commercial vaccine has been available against the H5N1 Clade 2.3.2.1a strain circulating within India. The development of an indigenous formulation is therefore considered a significant milestone for the country's animal health infrastructure. The vaccine is designed to offer targeted protection against the highly pathogenic strains currently prevalent in Indian poultry farms.
Scale of the Threat: Why This Vaccine Matters
Highly Pathogenic Avian Influenza (HPAI), commonly known as bird flu, can cause nearly 100 per cent mortality among infected bird populations, triggering mass culling events and severe disruptions to poultry trade. Since the disease was first detected in India in 2006, more than 500 combined outbreaks of H5N1 and H5N8 subtypes have been reported across the country, according to the Agriculture Ministry.
The economic consequences are stark. The 2006 bird flu outbreak alone caused estimated direct and indirect losses of ₹2,200–3,000 crore. A subsequent outbreak in Manipur resulted in losses equivalent to 0.5 per cent of that state's GDP. Projections suggest a major outbreak could shave up to 1.5 per cent off India's overall GDP growth, while more than 20 per cent of the country's poultry population could be at risk if the disease spreads unchecked.
Zoonotic Risk and Global Public Health Context
The threat is not confined to poultry farms. The World Health Organization (WHO) has recorded 1,003 human cases of H5N1 avian influenza, including 479 deaths, across 25 countries — including India — since 2003. In recent times, the Clade 2.3.2.1a strain has also been detected in multiple mammal species, alongside three human cases linked to the strain, raising concerns about cross-species transmission. Controlling its spread in poultry is therefore seen as a critical step in limiting wider zoonotic risk.
ICAR-NIHSAD's Role and What Comes Next
The vaccine has been developed at the ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD) in Bhopal, one of India's premier biosafety research facilities. The formal launch on 20 November by Minister Chouhan is expected to mark the transition from development to rollout planning. Wider deployment across India's poultry sector — which supports the livelihoods of millions of farmers — will depend on production scale-up and regulatory clearances in the coming months.